Genetic variants in EBV reactivation-related genes and the risk and survival of breast cancer
Tumor susceptibility gene 101 (TSG101) and activating transcription factor 2 (ATF2) have been suggested to involve in the reactivation of EBV which has implications in the development and progression of breast cancer. Therefore, the polymorphisms of TSG101 and ATF2 may associate with breast cancer risk and prognosis. A case-control study with 1551 breast cancer cases and 1605 age-matched controls were conducted in Guangzhou, China. We have also successfully followed up 1168 cases until December 31, 2014. The variant allele of TSG101 rs2292179 was associated with a non-significant reduced risk of breast cancer, particularly among women with BMI < 24 (kg/m2) (P for interaction <0.05). For ATF2 rs3845744, the variant allele was also associated with a significantly reduced breast cancer risk [odds ratio (OR) (95 % confidence interval (CI)) 0.86 (0.74∼1.00)], and the association occurred among only postmenopausal women [OR (95 % CI) 0.69 (0.54∼0.88)] (P for interaction <0.05). Breast cancer risk was further reduced with the increasing numbers of the variant G alleles of the two polymorphisms (P for trend <0.05). We did not find an overall association of the two loci with breast cancer prognosis, while the hazard ratios of the two loci (AG/GG vs. AA) were significantly higher among postmenopausal women than premenopausal women (P = 0.046, 0.016 for TSG101 rs2292179 and ATF2 rs3845744, respectively). In summary, the variant alleles of TSG101 rs2292179 and ATF2 rs3845744 were associated with a reduced risk of breast cancer, particularly for subjects with BMI <24 (kg/m2) and postmenopausal women, respectively. The two SNPs and menopausal status may have a significant interaction on breast cancer progression.
KeywordsTSG101 ATF2 Polymorphisms Prognosis Breast cancer
This work was supported by the National Natural Science Foundation of China (grant number: 81273147). The authors would like to thank all the study participants and nursing and administrative staff in the Breast Departments of The First and Second Affiliated Hospitals and Cancer Center, Sun Yat-sen University.
Compliance with ethical standards
Conflicts of interest
- 4.Richardson AK, Currie MJ, Robinson BA, Morrin H, Phung Y, Pearson JF, et al. Cytomegalovirus and Epstein-Barr virus in breast cancer. PLoS One. 2015;10:e118989.Google Scholar
- 6.De-The G, Day NE, Geser A, Lavoue MF, Ho JH, Simons MJ, Sohier R, Tukei P, Vonka V, Zavadova H: Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study—a review. IARC Sci Publ 1975:3-16Google Scholar
- 10.Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J, et al. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol. 2000;74:1224–33.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Bleiber G, May M, Martinez R, Meylan P, Ott J, Beckmann JS, et al. Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. J Virol. 2005;79:12674–80.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, et al. Levels of circulating regulatory CD4 + CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat. 2006;98:17–29.CrossRefPubMedGoogle Scholar